The Effect of a Probiotic Strain on Aspirin-induced GI Damage (PIP-L)

Chr. Hansen

Status: Terminated

Conditions: Reduction of Small Intestinal Ulceration Risk

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Bif195

Study type: Interventional

Funder types: Industry

Identifiers

NCT03910322

HND-GI-035

Details and patient eligibility

About

The primary objective of this trial is to investigate if a daily dose of minimum 50 billion CFU of Bif195 reduces the risk of small-intestinal tissue damage in an acetylsalicylic acid challenge model as assessed by video capsule endoscopy in a healthy US population aged 40 - 60 years.

Full description

This trial is a single-site, randomized, double-blind, placebo-controlled, three-armed, parallel-group trial in healthy volunteers aged 40 - 60 years. The trial will investigate the effect of daily intake of the probiotic strain Bif195 in two different doses or placebo when co-administered to daily intake of 300mg of Acetylsalicylic Acid (ASA).

The trial includes a run-in period of two weeks duration followed by a six weeks intervention period where Bif195/placebo and ASA is co-administered.

Subjects will participate in the trial for a total duration of 8 weeks including the run-in phase. Besides the screening visit, the trial will consist of 5 visits.

After having given their written informed consent, subjects will complete the screening procedures to evaluate their eligibility for participation in the trial and complete a run-in period of two weeks duration to washout possible pre-trial probiotics and/or use of medication. After baseline assessments at Visit 2, subjects will start daily intake of 300mg ASA and also be randomly assigned to 6-weeks daily intake of low or high-dose active (Bif195) or placebo product in a ratio of 1:1:1.

Enrollment: 30 patients

Sex: All

Ages: 40 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Written informed consent
• Healthy and without any gastrointestinal discomfort/pain symptoms
• Age 40-60 years of both genders (aim of minimum 1/3 of each gender in each arm)
• Willing and able to abstain from any other probiotic products and/or medication known to alter gastrointestinal function throughout the participation of the trial

Exclusion criteria

• Abdominal surgery which, as judged by the investigator, might affect the GI function (except appendectomy and cholecystectomy)
• History of peptic ulcer disease
• Any known bleeding disorder
• Allergy to ASA
• Resting diastolic blood pressure ≥ 95 mmHg
• Resting systolic blood pressure ≥ 150 mmHg
• A current diagnosis of psychiatric disease
• Systemic use of antibiotics, steroids (except contraceptives) or antimicrobial medication in the last 2 months
• Daily usage of non-steroidal anti-inflammatory drugs in the last 2 months or incidental use in the last 2 weeks prior to screening (ASA, Ibuprofen, Diclofenac, Naproxen, Celecoxib, Mefenamic acid, Etoricoxib, Indometacin)
• Usage of medications, except contraceptives, in the last 2 weeks prior to screening
• Diagnosed inflammatory gastrointestinal disease and/or irritable bowel syndrome
• Any other disease that, by the Investigators discretion, could interfere with the intestinal barrier function of the subject
• Participation in other clinical trials in the past 2 months prior to screening
• Regular use of probiotics in the last month
• Smoking and/or frequent use of other nicotine products
• Desire and/or plans on changing current diet and/or exercise regime during the participation of this trial
• Use of laxatives, anti-diarrheals, anti-cholinergics and proton pump inhibitors within last 2 months prior to screening
• Use of immunosuppressant drugs within last 4 weeks prior to screening
• For Women: Pregnancy or lactation

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

30 participants in 3 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo arm. Similar trial product, but without Bif195 bacteria

Treatment:

Dietary Supplement: Placebo

Low-dose Bif195

Experimental group

Description:

Active trial product with minimum 15 billion CFU daily dose

Treatment:

Dietary Supplement: Bif195

High-dose Bif195

Experimental group

Description:

Active trial product with minimum 50 billion CFU daily dose

Treatment:

Dietary Supplement: Bif195